Prostate specific membrane antigen (PSMA), which is specifically overexpressed on almost all prostate cancer cell membranes, is considered to be an ideal target for the diagnosis and treatment of prostate cancer; PSMA-mediated radionuclide therapy (PRRT) has also been a research hotspot in recent years. This evidence concerns the gene FOLH1 and Familial prostate cancer.